PMID- 37919137
OWN - NLM
STAT- MEDLINE
DCOM- 20240202
LR  - 20240410
IS  - 2152-2669 (Electronic)
IS  - 2152-2669 (Linking)
VI  - 24
IP  - 2
DP  - 2024 Feb
TI  - Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or 
      Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell 
      Lymphoma in the United States.
PG  - e21-e32.e4
LID - S2152-2650(23)02146-8 [pii]
LID - 10.1016/j.clml.2023.10.001 [doi]
AB  - INTRODUCTION/BACKGROUND: Primary cutaneous anaplastic large-cell lymphomas 
      (pcALCLs) are a type of cutaneous T-cell lymphoma (CTCL) in which CD30 is 
      uniformly expressed. In mycosis fungoides (MF), another CTCL, CD30 is 
      heterogeneously expressed. In ALCANZA, patients with pcALCLs or CD30-positive MF 
      randomized to brentuximab vedotin (BV) vs. physician's choice of methotrexate or 
      bexarotene had significantly improved outcomes, including higher objective 
      response rates (ORR) lasting >/=4 months (ORR4), as well as longer median 
      progression-free survival (PFS) and time to next treatment (TTNT). In this study, 
      we sought to assess the real-world impact of treatment with BV in second or later 
      lines of therapy for CTCL. MATERIALS AND METHODS: This retrospective chart review 
      describes patient characteristics, treatment patterns, clinical outcomes, and 
      healthcare resource use (HRU) in patients with pcALCLs or MF previously treated 
      with >/=1 systemic therapy and subsequently treated with BV (n = 139) or other 
      standard therapy (OST; n = 164). RESULTS: Most patients in the BV cohort (96.4%) 
      received BV as second-line (2L) systemic therapy. The most common OSTs were 
      methotrexate (11.6%), mogamulizumab (9.1%), and bendamustine (9.1%) 
      monotherapies. For 2L BV and OST, median duration of therapy was 8.4 and 5.2 
      months, real-world ORR was 82.1% and 66.5%, and real-world ORR4 was 42.5% and 
      25.0%. Real-world 1- and 2-year PFS, TTNT, and OS were significantly longer (all 
      P < .01) and HRU was lower for BV vs. OST. CONCLUSION: These real-world outcomes 
      are consistent with ALCANZA results, demonstrating favorable outcomes with BV vs. 
      OST in patients with CTCL previously treated with >/=1 systemic therapy.
CI  - Copyright (c) 2023 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Barta, Stefan K
AU  - Barta SK
AD  - Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, 
      Philadelphia, PA. Electronic address: Stefan.barta@pennmedicine.upenn.edu.
FAU - Liu, Nicholas
AU  - Liu N
AD  - Seagen Inc., Bothell, WA.
FAU - DerSarkissian, Maral
AU  - DerSarkissian M
AD  - Analysis Group, Inc., Boston, MA.
FAU - Chang, Rose
AU  - Chang R
AD  - Analysis Group, Inc., Boston, MA.
FAU - Ye, Mingchen
AU  - Ye M
AD  - Analysis Group, Inc., Boston, MA.
FAU - Duh, Mei Sheng
AU  - Duh MS
AD  - Analysis Group, Inc., Boston, MA.
FAU - Surinach, Andy
AU  - Surinach A
AD  - Genesis Research, Hoboken, NJ.
FAU - Fanale, Michelle
AU  - Fanale M
AD  - Seagen Inc., Bothell, WA.
FAU - Yu, Kristina S
AU  - Yu KS
AD  - Seagen Inc., Bothell, WA.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20231011
PL  - United States
TA  - Clin Lymphoma Myeloma Leuk
JT  - Clinical lymphoma, myeloma & leukemia
JID - 101525386
RN  - 7XL5ISS668 (Brentuximab Vedotin)
RN  - YL5FZ2Y5U1 (Methotrexate)
RN  - 0 (Immunoconjugates)
SB  - IM
MH  - Humans
MH  - United States
MH  - Brentuximab Vedotin/therapeutic use
MH  - Methotrexate
MH  - Retrospective Studies
MH  - *Lymphoma, T-Cell, Cutaneous/pathology
MH  - *Mycosis Fungoides/drug therapy
MH  - *Immunoconjugates/adverse effects
MH  - *Skin Neoplasms/drug therapy/pathology
OTO - NOTNLM
OT  - CD30
OT  - CTCL
OT  - Chart review
OT  - Healthcare resource utilization
OT  - Mycosis fungoides
COIS- Disclosure Stefan K. Barta: Consulting Fees: Affimed, Daiichi Sankyo, and Kyowa 
      Kirin; Payment or honoraria for educational events: Acrotech, Kyowa Kirin, and 
      Seagen Inc.; Membership: NCCN T-Cell and Cutaneous Lymphoma Panel; Nicholas Liu: 
      Employee of Seagen Inc.; Stock/Stock Options: Seagen Inc.; Maral DerSarkissian: 
      Employee of Analysis Group, which received research funding from Seagen Inc. to 
      conduct this study; Rose Chang: Employee of Analysis Group, which received 
      research funding from Seagen Inc. to conduct this study; Mingchen Ye: Employee of 
      Analysis Group, which received research funding from Seagen Inc. to conduct this 
      study; Mei Sheng Duh: Employee of Analysis Group, which received research funding 
      from Seagen Inc. to conduct this study; Andy Surinach: Employee of Genesis 
      Research, which received research funding from Seagen Inc. to conduct this study; 
      Michelle Fanale: Employee of Seagen Inc.; Stock/Stock Options: Seagen Inc.; 
      Kristina S. Yu: Employee of Seagen Inc.; Stock/Stock Options: Seagen Inc.
EDAT- 2023/11/03 00:42
MHDA- 2024/02/02 06:42
CRDT- 2023/11/02 22:55
PHST- 2023/07/11 00:00 [received]
PHST- 2023/10/02 00:00 [revised]
PHST- 2023/10/08 00:00 [accepted]
PHST- 2024/02/02 06:42 [medline]
PHST- 2023/11/03 00:42 [pubmed]
PHST- 2023/11/02 22:55 [entrez]
AID - S2152-2650(23)02146-8 [pii]
AID - 10.1016/j.clml.2023.10.001 [doi]
PST - ppublish
SO  - Clin Lymphoma Myeloma Leuk. 2024 Feb;24(2):e21-e32.e4. doi: 
      10.1016/j.clml.2023.10.001. Epub 2023 Oct 11.